SANDOZ ESOMEPRAZOLE DIN 02460939
Status: Marketed
Holder: SANDOZ CANADA INCORPORATED
Available to quote
Health Canada record
| Active ingredient(s) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG |
|---|---|
| Dosage form | Tablet (Delayed-Release) |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A02BC05 ESOMEPRAZOLE |
| Original market date | 25-Sep-2018 |
| Current status date | 25-Sep-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02417480 | ESOMEPRAZOLE | ETHYPHARM INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Approved |
| 02417499 | ESOMEPRAZOLE | ETHYPHARM INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Approved |
| 02379163 | PMS-ESOMEPRAZOLE DR | PHARMASCIENCE INC | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Approved |
| 02528487 | PMSC-ESOMEPRAZOLE DR | PHARMASCIENCE INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Marketed |
| 02528479 | PMSC-ESOMEPRAZOLE DR | PHARMASCIENCE INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Marketed |
| 02460920 | SANDOZ ESOMEPRAZOLE | SANDOZ CANADA INCORPORATED | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Marketed |
| 02423855 | TEVA-ESOMEPRAZOLE | TEVA CANADA LIMITED | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Marketed |
| 02423863 | TEVA-ESOMEPRAZOLE | TEVA CANADA LIMITED | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Marketed |
| 02535335 | ESOMEPRAZOLE | SANIS HEALTH INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Dormant |
| 02431173 | ESOMEPRAZOLE | SANIS HEALTH INC | Tablet (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Dormant |
| 02384337 | ESOMEPRAZOLE DR | LABORATOIRE RIVA INC. | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Cancelled Pre Market |
| 02384329 | ESOMEPRAZOLE DR | LABORATOIRE RIVA INC. | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Cancelled Pre Market |
| 02379171 | PMS-ESOMEPRAZOLE DR | PHARMASCIENCE INC | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Cancelled Post Market |
| 02386224 | RIVA-ESOMEPRAZOLE DR | LABORATOIRE RIVA INC. | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG | Cancelled Pre Market |
| 02386216 | RIVA-ESOMEPRAZOLE DR | LABORATOIRE RIVA INC. | Capsule (Delayed-Release) | ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 20 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18912 | 2017-01-30 | Abbreviated New Drug Submission (ANDS) | Licensing agreement between two companies |